Neuroscience technology innovator Cognivue, Inc. recently announced that Paul W. Estes has been promoted to president, ushering in the company’s next stage of market evolution.
According to a company’s news release, he will guide the executive leadership team and oversee the company’s technology roadmap planning, new product expansion, partnership relations, sales and staffing.
His appointment comes after 15 years of serving in increasingly senior positions with Cognivue. Estes joined the company in 2009, helping conceive and develop Cognivue technology, then played integral roles in its de novo 510(k) clearance from the U.S. Food and Drug Administration and subsequent commercialization. Most recently, he was Cognivue’s chief operating officer.
Estes succeeds Tom O’Neil, who left the company for a non-competitive leadership role in the healthcare infrastructure sector.
“Cognivue is headed into its next chapter of success, making it an even greater privilege to lead so many incredibly talented people throughout the company. Cognivue has several exciting developments ahead, such as the full-scale launch of our FDA-cleared next-generation technologies and continued participation in the groundbreaking Bio-Hermes clinical study with the Global Alzheimer’s Platform,” said Estes.